首页> 外文期刊>Journal of Pharmaceutical Analysis >Design and preparation of a new multi-targeted drug delivery system using multifunctional nanoparticles for co-delivery of siRNA and paclitaxel
【24h】

Design and preparation of a new multi-targeted drug delivery system using multifunctional nanoparticles for co-delivery of siRNA and paclitaxel

机译:使用多功能纳米粒子进行新型多目标药物递送系统的设计与制备用于共递送siRNA和紫杉醇

获取原文
           

摘要

Drug resistance is a great challenge in cancer therapy using chemotherapeutic agents. Administration of these drugs with siRNA is an efficacious strategy in this battle. Here, the present study tried to incorporate siRNA and paclitaxel (PTX) simultaneously into a novel nanocarrier. The selectivity of carrier to target cancer tissues was optimized through conjugation of folic acid (FA) and glucose (Glu) onto its surface. The structure of nanocarrier was formed from ternary magnetic copolymers based on FeCo-polyethyleneimine (FeCo-PEI) nanoparticles and polylactic acid-polyethylene glycol (PLA-PEG) gene delivery system. Biocompatibility of FeCo-PEI-PLA-PEG-FA(NPsA), FeCo-PEI-PLA-PEG-Glu (NPsB) and FeCo-PEI-PLA-PEG-FA/Glu (NPsAB) nanoparticles and also influence of PTX-loaded nanoparticles on in?vitro cytotoxicity were examined using MTT assay. Besides, siRNA-FAM internalization was investigated by fluorescence microscopy. The results showed the blank nanoparticles were significantly less cytotoxic at various concentrations. Meanwhile, siRNA-FAM/PTX encapsulated nanoparticles exhibited significant anticancer activity against MCF-7 and BT-474?cell lines. NPsAB/siRNA/PTX nanoparticles showed greater effects on MCF-7 and BT-474?cells viability than NPsA/siRNA/PTX and NPsB/siRNA/PTX. Also, they induced significantly higher anticancer effects on cancer cells compared with NPsA/siRNA/PTX and NPsB/siRNA/PTX due to their multi-targeted properties using FA and Glu. We concluded that NPsAB nanoparticles have a great potential for co-delivery of both drugs and genes for use in gene therapy and chemotherapy.
机译:耐药性是使用化学治疗剂癌症治疗的巨大挑战。用siRNA施用这些药物是这场战斗中有效的策略。这里,本研究试图将siRNA和紫杉醇(PTX)掺入新的纳米载体中。通过将叶酸(Fa)和葡萄糖(Glu)缀合到其表面上优化载体对靶癌组织的选择性。基于FeCo-聚乙烯亚胺(FeCo-PEI)纳米颗粒和聚乳酸 - 聚乙二醇(PLA-PEG)基因递送系统,由三元磁性共聚物形成纳米载体的结构。 FeCo-Pei-PLA-PEG-FA(NPSA),FECO-PEI-PEG-GLU(NPSB)和FECO-PEI-PLA-PEG-FA / GLU(NPSAB)纳米颗粒的生物相容性以及PTX负载的影响使用MTT测定检查纳米粒子体外细胞毒性。此外,通过荧光显微镜检查siRNA-FAM内化。结果表明,坯料纳米颗粒在各种浓度下显着减少细胞毒性。同时,SiRNA-FAM / PTX包封的纳米粒子对MCF-7和BT-474的显着抗癌活性表现出显着的抗癌活性。细胞系。 NPSAB / siRNA / PTX纳米粒子对MCF-7和BT-474的效果更大,比NPSA / siRNA / PTX和NPSB / siRNA / PTX对细胞活力。此外,与使用FA和Glu的多目标性质,它们诱导对癌细胞对癌细胞的显着更高的抗癌效应与NPSA / siRNA / PTX和NPSB / siRNA / PTX相比。我们得出结论,NPSAB纳米颗粒具有用于基因治疗和化疗的药物和基因的共同递送药物和基因的巨大潜力。

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号